P
Potenza Therapeutics
Preclinical-stage biotechnology company focused on building a portfolio of oncology programs
About Potenza Therapeutics
Potenza Therapeutics, founded in 2014, operated as a biotechnology firm focused on creating a portfolio of immuno-oncology programs. The company's core strategy was to develop therapies that modulate the body's immune system to identify and eliminate cancer cells. This approach centered on novel biological mechanisms that cancer cells use to evade detection by the immune system.
The company was co-founded by Daniel Hicklin, PhD, who also served as its President and CEO. Potenza's scientific advisory board comprised renowned pioneers in the field of cancer immunotherapy. In December 2014, the company secured $38 million in a Series A financing round led by MPM Capital, with participation from InterWest Partners and Astellas Venture Management LLC. This was followed by another early-stage venture capital round in December 2017.
Potenza's business model was rooted in research and development, culminating in a significant collaboration with the Japanese pharmaceutical company Astellas Pharma Inc. in April 2015. This partnership was established to jointly advance a portfolio of programs targeting immune checkpoint pathways, co-stimulatory signals, and regulatory T-cells. Under the agreement, Potenza was responsible for drug discovery and delivering development candidates, while Astellas handled clinical development and commercialization. This collaboration led to the discovery and development of three investigational new drugs designed to treat cancers that were non-responsive or resistant to existing immuno-oncology therapies.
The product pipeline included ASP8374/PTZ-201, an anti-TIGIT antibody (an immune checkpoint inhibitor); ASP1948/PTZ-329, an anti-NRP1 antibody (a Treg function inhibitor); and ASP1951/PTZ-522, a GITR agonistic antibody for T-cell priming and costimulation. In December 2018, Astellas exercised its option to acquire Potenza Therapeutics, making it a wholly-owned subsidiary. The acquisition involved an upfront payment of $164.6 million, with potential for up to $240.1 million in additional payments based on the clinical progress of the developed programs.
Source: Dealroom company dataNews
Open roles
Potenza Therapeutics in the Cambridge ecosystem
The Potenza Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
MPM BioImpact
InterWest Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Potenza Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Potenza Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

